Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 5/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPY1R | P25929 | 1/20 | 0.39 |
| ▸ | NPY2R | P49146 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7409790 | 0.88 | GAA (0.54) | POLBGAAHTTHPGDKDM4E | |
| SCHEMBL13561972 | 0.85 | GAA (0.68) | POLBGAAHTTHPGDKDM4E | |
| SCHEMBL7407421 | 0.81 | HTT (0.51) | POLBGAAHTTHPGDKDM4E | |
| SCHEMBL16662001 | 0.81 | GAA (0.51) | GAAHTTHPGDACHEKDM4E | |
| SCHEMBL167967 | 0.81 | POLB (0.51) | POLBGAAHTTACHEKDM4E | |
| SCHEMBL7414737 | 0.80 | GAA (0.50) | POLBGAAHTTHPGDKDM4E | |
| SCHEMBL7410882 | 0.80 | HTT (0.57) | POLBGAAHTTHPGDKDM4E | |
| SCHEMBL28919524 | 0.80 | POLB (0.57) | POLBGAAHTTHPGDACHE | |
| SCHEMBL28773479 | 0.79 | ACHE (0.47) | POLBGAAHTTHPGDACHE | |
| SCHEMBL7863946 | 0.79 | GAA (0.50) | GAAHTTHPGDKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| CN-118878461-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2024-11-01 | — | — | CN | disclosed |
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4100381-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2022-12-14 | — | — | EP | disclosed |
| CN-115413275-A | Substituted 1,1 , -biphenyl compounds and methods of use thereof | 爱彼特生物制药公司 | 2022-11-29 | — | — | CN | disclosed |
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-3612525-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2021-10-27 | — | — | EP | disclosed |
| WO-2021158481-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| EP-3612525-A1 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2020-02-26 | — | — | EP | disclosed |
| CN-110799509-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2020-02-14 | — | — | CN | disclosed |
| US-20180305315-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2018-10-25 | — | — | US | disclosed |
| WO-2018195321-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2018-10-25 | — | — | WO | disclosed |
| US-9365551-B2 | 2-(benzyloxy) benzamides as LRRK2 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2016-06-14 | — | — | US | disclosed |
| EP-2611772-B1 | 2-(BENZYLOXY)BENZAMIDES AS LRRK2 KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2014-09-24 | — | — | EP | disclosed |
| US-20130225584-A1 | 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-08-29 | — | — | US | disclosed |
| EP-2611772-A1 | 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012028629-A1 | 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225584-A1 | 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS | LRRK2, PARK7, BRSK2 | POLB 1496/4885GAA 226/4885HTT 379/4885 |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | POLB 529/4885GAA 3510/4885HTT 4067/4885 |
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | HAVCR2, HMBS, VHL | POLB 453/4885GAA 1601/4885HTT 241/4885 |
| US-20180305315-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | POLB 344/4885GAA 1061/4885HTT 4182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.